A Phase 3 interventional study of Methoxyflurane - Penthrox and Control in Benign Prostate Hypertrophy(BPH), sponsored by University of Manitoba. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by University of Manitoba · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Prostatic Hyperplasia with a site in Canada — 11 open to participants now, 16 under way, 3 of them phase 3. Prostatic Hyperplasia · Canada.
Among the 53 studies in Prostatic Hyperplasia with a site in Canada, this one is the 36th largest by planned enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 8 of the 15 other live ones, and was the 51st registered.
830 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.
Browse Prostatic Hyperplasia studies →11 of the 53 studies in Prostatic Hyperplasia with a site in Canada are open now. Recruiting first, the newest first:
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Men only
Thunder Bay Regional Health Research Institute · Sites in Canada
Ages 50+ · Men only
Société Internationale d'Urologie · Sites in Canada, United States, Chile and 18 more countries
Ages 18+ · Men only
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Men only
Thunder Bay Regional Health Research Institute · Sites in Canada
Ages 50+ · Men only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 15 · Phase 4 5
First in 2001; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 108 across the 47 interventional studies, 956 across the 5 observational. Of the 34 that completed or were terminated, 15 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 53 have an industry lead sponsor. The 10 most frequent:
University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
University of Manitoba has 3 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Prostatic Hyperplasia with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06769997Centre hospitalier de l'Université de Montréal (CHUM)Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia | 2027-01 |
| NCT07552961University of CalgaryFeasibility and Utility of a Prehabilitation Program for Use in Patients With Benign Prostatic Hyperplasia Who Have Elected to Undergo Holmium Laser Enucleation of the Prostate (HoLEP). | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Prostatic Hyperplasia with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary aim of the study is to show that methoxyflurane-lorazepam-percocet combination administrated 'per os' is non inferior to deep intravenous sedation in achieving analgesia during Rezum convective radiofrequency water vapor thermal therapy for the management of benign prostate hyperplasia (BPH). We propose to conduct a single-centered, unblinded, randomized controlled trial designed after consulting ICH Guidelines for Good Clinical Practice as well the regulations set by the Biomedical Research Ethics Board, University of Manitoba.
Participants who belong to the experimental arm will be given a single 'per os' dose of percocet (325mg acetaminophen + 7.5mg oxycodone) and lorazepam 1 mg, 30 minutes prior to the procedure. Patients will receive education on how to use the Penthrox inhaler device. Inside the operating room, the subject would self-inhale the methoxyflurane 5 minutes prior to the procedure. All these steps will be supervised by the clinical research nurse. Each participant will be administered with 3ml of methoxyflurane which is poured into the inhaler. Participants who were randomized to the control arm will receive deep intravenous sedation under the supervision of a trained anesthetist. A combination of midazolam, ketamine, remifentanil and propofol will be administered using an intravenous line. The quantity of these medications will be calculated by the anesthetist based on clinical judgement and also takes into account the physical characteristic of the subject. Both the groups receive the same Rezum water vapor therapy and the number of Rezum injections depends on the clinical judgement of the urologist performing the procedure. Immediately, post the procedure, the self-reported pain of the patient will be recoded using the NRS. A phone call follow-up would be done the following day to record any adverse events caused due to the procedure. Four weeks post the procedure, a phone call follow-up would be done to understand the patient satisfaction after the surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants can begin using penthrox 10 minutes prior to procedure start, given its median onset time of 5 minutes
Drug: Methoxyflurane - Penthrox · Drug: Percocet Pill · Drug: Lorazepam (drug)
Patients will receive standard of care during their rezum procedure which consists of deep IV sedation.
Other: Control
Penthrox is a brand name for a drug called methoxyflurane. It is an inhaled analgesic (pain-relieving) agent used primarily for the relief of moderate to severe pain, typically in emergency medical situations or during minor medical procedures. Penthrox is administered by inhaling the vapors through a hand-held inhaler device. It acts quickly to provide pain relief and has a relatively short duration of action.
This intervention will be the control group only, receiving deep IV sedation.
Percocet will be given in conjunction with methoxyfluorane and lorazepam
Lorazepam will be given in conjunction with penthrox and percocet.
Post-Procedural Pain
Post procedural pain measured using the Numeric Rating Scale for pain. Higher scores on this measurement indicate worser outcomes. Maximum value of 10 and a minimum value of 10 can be reported on this scale.
Time frame: Immediately post-procedure
Safety of Procedure
The safety of combination vs deep intravenous sedation during Rezum will be measured by accounting for adverse event encountered during the procedure.
Time frame: At time of procedure and post-procedure
Cost-effectiveness,
We will compare the costs associated with the procedure in both arms to see if there is any difference.
Time frame: 1 month post-procedure
Anxiety levels
We will measure anxiety levels using the Amsterdam Pre-Operative Anxiety and Information Scale (APAIS). Higher scores indicate worser outcomes. Maximum value of 30 and a minimum value of 0. It is a 6 part questionnaire which each question is given on a likert scale from 1-5
Time frame: Pre-Procedure on day of procedure
Patient satisfaction
We will measure patient satisfaction using a likert scale single question patient satisfaction questionnaire. (higher scores indicate better outcomes). Maximum value of 5 and a minimum value of 0.
Time frame: Immediately post-procedure
Start is estimated for Aug 2025; primary completion for Dec 2025, 4 months later.
Of 17 phase 3 interventional studies under Prostatic Hyperplasia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorazepam